Covid-19: Handling of Marketing Authorisations
![Drug Master File Procedures in the EU, the US and Japan - Live Online Training](files/eca/userImages/training.img/Z-ECA-Drug-Master-File-Procedures-LOT.jpg)
Recommendation
17/18 September 2024
With updates on the CEP 2.0!
The processes and procedures relating to marketing authorisations are still strongly influenced by the corona pandemic. On the website of the HMA (Heads of Medicines Agencies) this has been reiterated and the available templates and information to facilitate and manage marketing authorisations and registration procedures have been consolidated and listed.
In addition to the continuously updated catalogue"QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC", the "Template for submission of an application for a Covid-19 exeptional change management process (ECMP)" and the "Template for Step 3 Notification of implementation" are available here.
The overview of the information provided and application templates can be found on the website of the HMA (Heads of Medicines Agencies) in the section CMDh.
Related GMP News
17.07.2024EMA: Q&A document for "Centralised Procedures" updated again
16.07.2024CMDh/HMA: New Update of the Q&A List on Variations
18.06.2024EDQM: New Guideline for sterile Substances published for Comment
18.06.2024EMA updates IRIS Guide
02.05.2024EDQM: Updated Information on the Quality Overall Summary (Module 2)
02.05.2024EDQM: Manufacturing Sites in CEP 2.0?